Vaxxinity (VAXX)
(Delayed Data from OTC)
$0.00 USD
0.00 (900.00%)
Updated Aug 30, 2024 09:31 AM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
VAXX 0.00 0.00(900.00%)
Will VAXX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VAXX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VAXX
The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity
Alzheimer's Disease Space Evolves in 2023: Stocks in Focus
VAXX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merck's (MRK) Meets Goal in Muscle-Invasive Bladder Cancer Study
ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data
Sanofi (SNY) Inks Deal With J&J to Develop E. coli Vaccine
Other News for VAXX
Vaxxinity UB-312 Parkinson?s Trial Results Published in Nature Medicine
Vaxxinity's Parkinson's candidate UB-312 demonstrates efficacy in publication